MedTrace Logo

Superselective Intra-arterial Chemotherapy Treatment for Retinoblastoma- 5 Year Results From Turkey

NCT03935074 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2019-05-06

No results posted yet for this study

Summary

Retrospective review of 5-year long term outcomes of superselective intra-arterial chemotherapy treatment in retinoblastoma in a single institute.

The treatment outcomes, globe salvage rates and complications of superselective intra-arterial chemotherapy both for treating naive patients (primary treatment group) and for patients who received systemic chemotherapy previously (secondary treatment group) were evaluated.

Conditions

  • Retinoblastoma

Interventions

DRUG

intra-arterial administration of melphalan

Sponsors & Collaborators

  • Istanbul University - Cerrahpasa

    lead OTHER

Eligibility

Min Age
5 Months
Max Age
7 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-30
Primary Completion
2016-11-30
Completion
2016-11-30

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03935074 on ClinicalTrials.gov